Justin Kunz, DO
Psychiatry · Billings, MTNPI 1902433006
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 192 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AbbVie at 34.5% of the total. Reporting peaked in 2023 at $1,905 and has fallen 52.7% since, to $901 in 2024. Among psychiatry clinicians in MT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 192 payments — averaging $19.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Johnson & Johnson$515
- Otsuka America Pharmaceutical, Inc.$441
- Neurocrine Biosciences, Inc.$410
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$314
- Vanda Pharmaceuticals Inc.$143
- plus $687 from 10 others
What the payments were for
- Food & beverage$3,832100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 55 | $1,322 |
| Johnson & Johnson | 35 | $515 |
| Otsuka America Pharmaceutical, Inc. | 20 | $441 |
| Neurocrine Biosciences, Inc. | 23 | $410 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 15 | $314 |
| Vanda Pharmaceuticals Inc. | 10 | $143 |
| Lundbeck LLC | 7 | $126 |
| Teva Pharmaceuticals USA, Inc. | 6 | $124 |
| Alkermes, Inc. | 6 | $121 |
| Ironshore Pharmaceuticals Inc. | 4 | $89 |
| Supernus Pharmaceuticals, Inc. | 3 | $60 |
| Axsome Therapeutics, Inc. | 2 | $54 |
| Corium, LLC | 2 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Almatica Pharma LLC | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $12 |
How this compares
$3,832 in reported general payments places this provider in the 95th percentile of 82 psychiatry providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 17 | $422 |
| Quetiapine Fumarate | 18 | $183 |
| Prazosin Hcl | 14 | $178 |
| Mirtazapine | 19 | $177 |
| Trazodone Hcl | 21 | $174 |
| Buspirone Hcl | 16 | $153 |
| Escitalopram Oxalate | 11 | $119 |
| Clonazepam | 18 | $103 |
| Lamotrigine | 14 | $97 |
| Bupropion XlBupropion Hcl | 14 | $95 |
| Fluoxetine Hcl | 16 | $66 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Billings
- Troy StilesBillings$221K
- Erin AmatoBillings$88K
- Reza Hosseini GhomiBillings$6K
- Svetlana YakovBillings$2K
- Faraz MasoodBillings$1K
- Eric ArzubiBillings$353
- Deborah MaltersBillings$284
- Katherine WeaverBillings$168
- Mariela Herrera RojasBillings$98
- Todd WojtanowiczBillings$86
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.